196 related articles for article (PubMed ID: 32751892)
1. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile.
Astolfi A; Nannini M; Indio V; Schipani A; Rizzo A; Perrone AM; De Iaco P; Pirini MG; De Leo A; Urbini M; Secchiero P; Pantaleo MA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751892
[TBL] [Abstract][Full Text] [Related]
2. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
3. Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
[TBL] [Abstract][Full Text] [Related]
4. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
6. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.
Dall GV; Hamilton A; Ratnayake G; Scott C; Barker H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326717
[TBL] [Abstract][Full Text] [Related]
7. Characterizing genomic differences of human cancer stratified by the TP53 mutation status.
Wang M; Yang C; Zhang X; Li X
Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617
[TBL] [Abstract][Full Text] [Related]
8. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
[TBL] [Abstract][Full Text] [Related]
9. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
Mäkinen N; Aavikko M; Heikkinen T; Taipale M; Taipale J; Koivisto-Korander R; Bützow R; Vahteristo P
PLoS Genet; 2016 Feb; 12(2):e1005850. PubMed ID: 26891131
[TBL] [Abstract][Full Text] [Related]
10. Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors.
Chen L; Li J; Wu X; Zheng Z
Front Oncol; 2021; 11():687899. PubMed ID: 34178683
[TBL] [Abstract][Full Text] [Related]
11. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
[TBL] [Abstract][Full Text] [Related]
12. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
13.
Williams EA; Sharaf R; Decker B; Werth AJ; Toma H; Montesion M; Sokol ES; Pavlick DC; Shah N; Williams KJ; Venstrom JM; Alexander BM; Ross JS; Albacker LA; Lin DI; Ramkissoon SH; Elvin JA
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015533
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
15. Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in
Watson AP; Shabaneh A; Wang J; Dehm SM; Rao A; Ryan CJ
Am J Clin Exp Urol; 2020; 8(4):106-115. PubMed ID: 32929406
[TBL] [Abstract][Full Text] [Related]
16. The mutational repertoire of uterine sarcomas and carcinosarcomas in a Brazilian cohort: A preliminary study.
da Costa LT; Dos Anjos LG; Kagohara LT; Torrezan GT; De Paula CAA; Baracat EC; Carraro DM; Carvalho KC
Clinics (Sao Paulo); 2021; 76():e2324. PubMed ID: 33503190
[TBL] [Abstract][Full Text] [Related]
17. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
18. Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.
Yang CY; Liau JY; Huang WJ; Chang YT; Chang MC; Lee JC; Tsai JH; Su YN; Hung CC; Jeng YM
Am J Transl Res; 2015; 7(10):2072-81. PubMed ID: 26692951
[TBL] [Abstract][Full Text] [Related]
19. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract][Full Text] [Related]
20. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
Oncologist; 2024 May; ():. PubMed ID: 38716772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
